List view / Grid view
Eli Lilly and Company have announced executive leadership changes and…
Eli Lilly and Company have announced executive leadership changes and the creation of neuroscience and immunology business units.
A study of baricitinib in combination with remdesivir has met…
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
A Phase III trial has been launched to study whether…
A Phase III trial has been launched to study whether baricitinib, an oral JAK1/JAK2 inhibitor, is effective at combatting COVID-19 in hospitalised patients.
Eli Lilly has announced it is to acquire Dermira for $18.75 per…
Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.
According to Eli Lilly, the company will acquire Dermira in…
According to Eli Lilly, the company will acquire Dermira in an all-cash transaction for $1.1 billion, at a rate of $18.75 per share.
